LuNET-3: Somatostatin receptor-targeted radioligand therapy (RLT) in patients with pancreatic neuroendocrine Tumours in Germany (EANM 2026) - Sep 29, 2026 - Abstract #EP-0871; "Prior therapies: somatostatin analogs 86%: octreotide LAR 29.4%, lanreotide 42%; everolimus 13%; chemotherapy 33%. On average, 3.6 RLT cycles (median 4) [177Lu]Lu-DOTA-TATE; mean cumulative activity 25.7 GBq... SSTR-targeted RLT is an effective and well-tolerated option in routine German care for patients with advanced pancreatic NET. Response rates, PFS, and OS are consistent with prospective data and support the use of RLT in this population, also in an early therapy line. Safety events were consistent with known profiles."
Clinical • Gastrointestinal Neuroendocrine Tumor • Hematological Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR
|
|
M. Schmidt 1; N. Trautwein 2; C. LaFougere 2; B. Kreppel 3; M. Essler 3; C. Däubler 4; A. Weich 5; S. Ezziddin 6; F. Eilsberger 7; M. Beck 8; A. Küper 9; K. Pabst 9; W. Fendler 9; H. Lahner 10; K. Herrmann 9; D. Waldschmidt 11; M. Pavel 12
|